TY  - GEN
A1  - Hocher, Berthold
A1  - Tsuprykov, Oleg
T1  - Renoprotective effects of GLP1R agonists and SGLT2 inhibitors
T2  - Nature reviews nephroloy
N2  - New data from the LEADER trial show that the glucagon-like peptide 1 receptor agonist liraglutide protects against diabetic nephropathy in patients with type 2 diabetes mellitus. The renoprotective efficacy of liraglutide is not, however, as great as that reported for the sodium-glucose cotransporter 2 inhibitor emplagiflozin in the EMPA-REG OUTCOME trial.
Y1  - 2017
UR  - https://publishup.uni-potsdam.de/frontdoor/index/index/docId/49312
SN  - 1759-5061
SN  - 1759-507X
VL  - 13
SP  - 728
EP  - 729
PB  - Nature Publ. Group
CY  - New York
ER  -